Results 11 to 20 of about 2,882,240 (203)

Primary resistance to integrase strand-transfer inhibitors in Europe. [PDF]

The Journal of antimicrobial chemotherapy, 2015
The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance.This was a multicentre, cross-sectional study within the European SPREAD HIV resistance surveillance programme. A representative set of 300 samples
Casadellà, M, van Ham, P M, Noguera-Julian, M, van Kessel, A, Pou, C, Hofstra, L M, Santos, J R, Garcia, F, Struck, D, Alexiev, I, Bakken Kran, A M, Hoepelman, A I, Kostrikis, L G, Somogyi, S, Liitsola, K, Linka, M, Otelea, D, Paraskevis, D, Poljak, M, Puchhammer-Stöckl, E, Staneková, D, Stanojevic, M, Van Laethem, K, Zidovec Lepej, S, Clotet, B, Boucher, C A B, Paredes, R, Wensing, A M J, Pedersen, Court   +28 more
core   +19 more sources

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. [PDF]

PLoS ONE, 2017
T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor (INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the prevalence of T97A (pre-existing and emergent) and its impact on INSTI ...
Michael E Abram, Renee R Ram, Nicolas A Margot, Tiffany L Barnes, Kirsten L White, Christian Callebaut, Michael D Miller   +6 more
doaj   +2 more sources

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +2 more sources

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs [PDF]

Viruses, 2021
Integrase strand transfer inhibitors (INSTIs) are currently recommended for the first line treatment of human immunodeficiency virus type one (HIV-1) infection. The first-generation INSTIs are effective but can select for resistant viruses. Recent advances have led to several potent second-generation INSTIs that are effective against both wild-type (WT)
Steven J. Smith, Xue Zhi Zhao, Dario Oliveira Passos, Dmitry Lyumkis, Terrence R. Burke, Stephen H. Hughes   +5 more
openaire   +4 more sources

Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors

Journal of Inorganic Biochemistry, 2013
The quinolone HL(1) and the hydroxypyrimidine-carboxamide HL(2) were designed and synthesized as models of the HIV integrase strand transfer inhibitors Elvitegravir and Raltegravir (brand name Isentress), with the aim to study their complexing behavior and their biological activity. The Ru(arene) complexes [RuCl(η(6)-p-cym)L(1)], [RuCl(η(6)-p-cym)L(2)]
CARCELLI, Mauro, BACCHI, Alessia, PELAGATTI, Paolo, G. Rispoli, ROGOLINO, Dominga, T. W. Sanchez, M. Sechi, N. Neamati   +7 more
openaire   +5 more sources

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence [PDF]

Viruses, 2015
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem of drug resistance through de novo emergence of such variants.
Thibault Mesplède, Mark A. Wainberg
openaire   +4 more sources

Patterns of resistance development with integrase inhibitors in HIV [PDF]

Infection and Drug Resistance, 2011
Jean L Mbisa, Supang A Martin, Patricia A CaneVirus Reference Department, Microbiology Services, Health Protection Agency, London, UKAbstract: Raltegravir, the only integrase (IN) inhibitor approved for use in HIV therapy, has recently been licensed ...
Jean L Mbisa, Supang A Martin, Patricia A Cane   +2 more
doaj   +2 more sources

Exploring Zinc C295 as a Dual HIV-1 Integrase Inhibitor: From Strand Transfer to 3′-Processing Suppression

Pharmaceuticals
Background: The global AIDS pandemic highlights the urgent need for novel antiretroviral therapies (ART). In our previous work, Zinc C295 was identified as a potent HIV-1 integrase strand transfer (ST) inhibitor. This study explores its potential to also
Sharif Karim Sayyed, Marzuqa Quraishi, D. S. Prabakaran, Balaji Chandrasekaran, Thiyagarajan Ramesh, Satish Kumar Rajasekharan, Chaitany Jayprakash Raorane, Tareeka Sonawane, Vinothkannan Ravichandran   +8 more
doaj   +2 more sources

Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors

Journal of Medicinal Chemistry, 2005
Using a training set of diketo-like acid HIV-1 integrase (IN) strand-transfer inhibitors, a 3D pharmacophore model was derived having quantitative predictive ability in terms of activity. The best statistical hypothesis consisted of four features (one hydrophobic aromatic region, two hydrogen-bond acceptors, and one hydrogen-bond donor) with r of 0.96.
BARRECA, Maria Letizia, FERRO, Stefania, RAO, Angela, DE LUCA, Laura, ZAPPALA', Maria, MONFORTE, Anna Maria, Z. DEBYSER, M. WITVROUW, CHIMIRRI, Alba   +8 more
openaire   +4 more sources

Corrigendum to: Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. [PDF]

Clin Infect Dis, 2022
Corrigendium to: "Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens among Adults with Human Immunodeficiency ...
Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, Silverberg MJ, Buchacz K, Li J, Edwards JK, Rebeiro PF, Lima VD, Marconi VC, Sterling TR, Horberg MA, Gill MJ, Kitahata MM, Eron JJ, Moore RD.   +18 more
europepmc   +2 more sources